Method of treating peripheral nerve disorders

a peripheral nerve and disorder technology, applied in the field of peripheral nerve disorders, can solve the problems of mild difficulty in walking, vascular damage, and unfavorable local tissue destruction

Inactive Publication Date: 2016-06-16
VOLUTION IMMUNO PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The EV576 protein effectively reduces the severity of peripheral nerve disorders by inhibiting C5a and MAC formation, offering a potential human therapy for conditions like Guillain-Barré Syndrome and CIDP, with a lower risk of concomitant infection compared to targeting earlier complement cascade products.

Problems solved by technology

Complement can be activated inappropriately under certain circumstances leading to undesirable local tissue destruction.
Similarly in cardiopulmonary bypass operations, the body recognises the plastic surfaces in the machine as foreign, activates complement and can result in vascular damage.
The symptoms may stay in this phase, causing only mild difficulty in walking, requiring crutches or a walking stick.
However, sometimes the illness progresses, leading to complete paralysis of the arms and legs.
Ventilation, plasmapheresis and immunoglobulin are extremely expensive.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating peripheral nerve disorders
  • Method of treating peripheral nerve disorders
  • Method of treating peripheral nerve disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

1. Mechanism of Action and Inhibitory Concentration.

[0067]EV576 was purified from salivary gland extracts of the soft tick Orthinodoros moubata by SDS-PAGE and RP-HPLC of fractions of salivary gland extract found to contain complement inhibitory activity by classical haemolytic assays (FIG. 3) as disclosed in [19].

[0068]EV576 inhibits both human and guinea pig classical and alternative pathways. It has no effect on the rate of C3a production (FIG. 4A) but prevents cleavage of C5a from C5 (FIG. 4B).

[0069]The ability of EV576 to inhibit both the classical and the alternative complement pathways is due to binding of the molecule to complement C5, the precursor of C5a and C5b-9. EV576 binds directly to C5 (FIG. 4C) with an IC50 of ≈0.02 mg / ml. The precise binding mechanism and accessory roles (if any) played by serum factors are under investigation.

[0070]Recombinant EV576 (rEV576) with glycosylation sites removed (which otherwise are glycosylated in the yeast expression system) is as ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This patent application is a division of U.S. patent application Ser. No. 12 / 440,462, a National Stage Entry of International Patent Application No. PCT / GB2007 / 003401, filed on Sep. 10, 2007, which claims priority to GB 0617734.9, filed on Sep. 8, 2006 (now abandoned), the entire contents of each of which are hereby incorporated by reference herein.SEQUENCE LISTING[0002]The present specification makes reference to a Sequence Listing (submitted electronically as a .txt file named “2011203-0022_Sequence_Listing” on Nov. 12, 2015). The .txt file was generated on Nov. 12, 2015 and is 2.6 kilobytes in size. The entire contents of the Sequence Listing are herein incorporated by reference.[0003]The present invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders.[0004]All documents m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K38/17A61K45/06A61K9/00
CPCA61K38/1767A61K48/00A61K45/06A61K9/0019A61K38/17A61P17/00A61P17/04A61P25/00A61P25/02A61P25/14A61P9/00A61P9/14
InventorHAMER, JOHN
OwnerVOLUTION IMMUNO PHARMA